Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2b + Ribavirin in Compensated Liver Cirrhosis
NCT00687219Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2007
- Primary completion
- Oct 2010
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b in hepatitis C (HCV), sponsored by Merck & Co.. Started Jun 2007; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00687219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687219.